antibiotic development

This is a rare feel-good moment in the antibiotic space.  Shionogi manufactures and markets cefiderocol, a beta-lactam antibiotic that utilizes a clever siderophore strategy to enter and kill multi-resistant Gram-negative pathogens.

Here we go again. Entasis Therapeutics has been struggling in the public marketplace.

This blog was inspired by a recent conversation with a CEO of a clinical phase antibiotic biotech.

Obvious from the title, today’s blog is going to ramble a bit. I don’t apologize.   

In researching the current status of pull incentives for antibiotic research and development in Europe I came across an ongoing tension.

Lately I have become intrigued by the word, innovation. Innovation is used as a criterion for funding grants, for status in reviews of our antibiotic pipeline, for intelligence, imagination and many other great things.

Abbvie is buying Allergan – but not for its antibiotic franchise.  They are more interested in Botox and other esthetic produ